Published Paper Details:

Diabetes and cardiovascular disease are rising global health concerns and in around 85% of cases, patients are having both these diseases as a comorbid condition. Such patients administer drugs belonging to both antidiabetic and antihyperlipidemic class. Managing diabetes mellitus along with cardiovascular disease is done by controlling blood glucose level and cholesterol level by adapting antidiabetic and antihyperlipidemic drug therapy respectively with their simultaneous administration. Selection of the most accurate drugs and their effective dose regime is very important to avoid further severe complications. Empagliflozin is prescribed as a first-line drug for diabetes treatment and Atorvastatin is the preferred one in cardiovascular disease. The dual effect of Atorvastatin on the blood glucose level creates a need for monitoring of its concentration in patients consuming simultaneously an antidiabetic drug like Empagliflozin. The proposed method is an attempt to develop an HPTLC method for simultaneous estimation of Atorvastatin and Empagliflozin in human plasma. Chromatographic separation of drugs was performed over TLC plates pre-coated with silica gel 60F254 using toluene: ethyl acetate: methanol: formic acid (12:5:3:0.5 v/v/v/v) as the mobile phase via a linear ascending technique. Detection and quantification were carried out at a wavelength 235 nm. The method was validated according to the European Medicines Agency ICH guideline M10 on Bioanalytical Method Validation and gave satisfactory results. The developed method can be successfully employed for simultaneous estimation of Empagliflozin and Atorvastatin from human plasma of patients with the comorbid condition of diabetes and cardiovascular disease.